January 17th 2025
A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.
January 17th 2025
January 16th 2025
January 15th 2025
January 14th 2025
January 5th 2025
January 1st 2025
December 31st 2024
December 29th 2024
January 12th 2025
January 7th 2025
November 30th 2024
November 27th 2024